INTELLIGENT BIO SOLUTIONS INC. INBS
refer to Intelligent Bio Solutions Inc. together with its wholly owned subsidiaries.
Bio Solutions Inc. and its wholly owned Delaware subsidiary, GBS Operations Inc., were each formed on December
5, 2016, under the laws of the state of Delaware. The Company's Australian subsidiary, Intelligent Bio Solutions (APAC) Pty Ltd, was formed on August 4, 2016, under the laws of New South Wales,
Australia. On October 4, 2022, INBS acquired Intelligent Fingerprinting Limited ("IFP"), a company registered in England
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $3.1M | $3.1M | $1.3M | $437.1K | $2.0M | $188.7K | — |
| Cost of revenue | $2.2M | $1.8M | $1.7M | $930.2K | — | — | — | — |
| Gross profit | $2.0M | $1.2M | $1.4M | $326.7K | — | — | — | — |
| SG&A | $10.5M | $8.9M | $9.3M | $8.0M | $4.9M | $3.4M | $2.2M | — |
| Total operating expenses | $15.3M | $12.7M | $12.1M | $13.7M | $8.8M | $7.6M | $3.0M | — |
| Operating income | -$12.6M | -$10.7M | -$10.3M | -$12.6M | -$8.3M | -$5.6M | -$2.9M | — |
| Interest expense | $10.7K | $26.3K | $167.1K | — | — | — | — | — |
| Pre-tax income | — | — | — | — | — | -$7.1M | -$3.2M | — |
| Net income | -$12.4M | -$10.6M | -$10.2M | -$10.6M | -$8.3M | -$7.0M | -$3.2M | — |
| EPS, basic | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 | -0.68 | — | — |
| EPS, diluted | -8.44 | -20.04 | -6.38 | -127.00 | -11.33 | -0.68 | -0.37 | — |
| Shares, diluted (wtd. avg.) | $1.5M | $527.4K | $1.6M | $83.7K | $733.3K | $10.4M | — | — |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.0M | $1.0M | $6.3M | $1.5M | $8.2M | $12.6M | $427.3K | — |
| Receivables | $848.5K | $594.6K | $429.7K | $293.9K | — | — | — | — |
| Inventory | $418.6K | $635.2K | $777.5K | $979.9K | — | — | — | — |
| Total current assets | $7.1M | $4.1M | $8.5M | $3.9M | $10.9M | $18.2M | $2.3M | — |
| Property, plant and equipment | $294.4K | $251.3K | $565.9K | $690.2K | $391.4K | — | — | — |
| Goodwill | — | — | — | — | $3.8M | — | — | — |
| Other intangibles | $2.8M | $3.8M | $4.4M | $5.3M | — | — | — | — |
| Total assets | $11.9M | $8.2M | $13.8M | $10.4M | $12.4M | $21.9M | $2.5M | — |
| Accounts payable | $712.4K | $897.3K | $1.7M | $2.6M | $1.6M | $1.5M | $787.5K | — |
| Total current liabilities | $4.9M | $5.4M | $5.5M | $5.9M | $4.7M | $3.7M | $7.7M | — |
| Long-term debt | — | — | — | $1.6M | — | — | — | — |
| Total liabilities | $6.7M | $5.4M | $5.6M | $6.7M | $5.8M | $6.9M | $7.7M | — |
| Retained earnings | -$75.0M | -$62.5M | -$52.0M | -$41.8M | -$31.2M | -$22.9M | -$15.8M | — |
| Total equity | $5.5M | $3.0M | $8.2M | $3.7M | $6.5M | $15.0M | -$5.2M | -$4.0M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.9M | -$9.7M | -$9.6M | -$7.4M | -$3.4M | -$11.3M | -$498.6K | — |
| Depreciation and amortisation | $68.3K | $27.1K | $974.4K | $814.5K | $0 | — | — | — |
| Stock-based compensation | $195.2K | $238.0K | $230.5K | $260.0K | — | — | — | — |
| Capital expenditure | $125.7K | $231.8K | $221.4K | — | — | — | — | — |
| Investing cash flow | -$85.6K | -$231.8K | -$221.4K | -$694.1K | -$880.2K | — | -$14.0K | — |
| Financing cash flow | $15.0M | $4.6M | $14.6M | $1.4M | — | $23.4M | $733.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-039136.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |